Axsome Therapeutics에 대한 매도 수량은 투자자에게 Axsome Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Axsome Therapeutics (NASDAQ:AXSM) 주식, 공매도 수량 보고

AXSOME THERAPEUTICS INC

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Uber Weride

Equities

Mid Cap

News

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

NVDA

RXRX

SWTX

TEVA

VNET

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 위라이드(NASDAQ:WRD)의 주식이 97.62% 급등했다. 이는 엔비디아(NASDAQ:NVDA)가 13F 제출을 통해 174만 주의 지분을 보유하고 있다고 공개한 후 발생한 일이다.

위라이드, 크리스퍼 및 진DX 등 지난주 최대 상승한 10개의 중형주 (2월 10일-2월 14일)

Axsome Therapeutics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and lowers the price target from $200 to $180.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Lowers Price Target to $180

Wells Fargo analyst Cerena Chen maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight and raises the price target from $160 to $165.

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $165

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $160 to $162.

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $162

Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $119.87 million.</a>
Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190347/axsome-therapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">up 80% year over year</a>.
Approximately 167,000 prescriptions were written for Auvelity in Q1 of 2025. This represents an increase of 76% compared to the same period in 2024 and an increase of 5% compared to the fourth quarter of 2024.
Sunosi, a sleep disorder medicine, generated net product revenues of $25.2 million, up 17%.
Approximately 46,000 prescriptions were written for Sunosi in the U.S., representing an increase of 12% compared to the same period in 2024, but a decrease of 5% compared to the fourth quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
The company reported an adjusted net loss of 68 cents.
Net loss for the first quarter of 2025 was $59.4 million, or $1.22 per share. Compare that to a net loss of $68.4 million, or $1.44 per share, for the comparable period in 2024.
The net loss in the first quarter of 2025 includes $26.2 million in non-cash charges, primarily $23.3 million in stock-based compensation expenses.
FDA Approval: The FDA approved Axsome Therapeutics&#8217; Symbravo (meloxicam and rizatriptan). This treatment is for the acute treatment of migraine with or <a href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" target="_blank" rel="noreferrer noopener">without aura in adults</a>.
The company expects SYMBRAVO to be commercially available in the U.S. in approximately four months (June 2025).
Development Pipeline: 
AXS-05 (dextromethorphan-bupropion)
<ul>
<li>Alzheimer&#8217;s Disease Agitation: In March, Axsome received formal pre-NDA meeting minutes from the FDA for AXS-05 in AD agitation, supporting a supplemental NDA (sNDA) submission. The company is on track to submit the sNDA in the third quarter of 2025. </li>
<li>Smoking Cessation:&nbsp;Axsome plans to initiate a pivotal Phase 2/3 trial of AXS-05 in smoking cessation in 2025.</li>
</ul>
<ul>
<li>Solriamfetol (dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist): In March, Axsome announced topline results from the FOCUS Phase 3 trial evaluating the efficacy and safety of solriamfetol in Attention Deficit Hyperactivity Disorder (ADHD) in adults. The company plans to initiate a Phase 3 trial of solriamfetol in ADHD in <a href="https://www.benzinga.com/25/03/44475435/axsome-therapeutics-lower-dose-of-attention-deficient-disorder-candidate-hits-primary-goal" target="_blank" rel="noreferrer noopener">pediatric patients in 2025</a>. </li>
<li>SYMBRAVO (MoSEIC meloxicam-rizatriptan): In February 2025, Axsome announced topline results from the EMERGE Phase 3 trial of Symbravo in migraine patients experiencing inadequate response <a href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" target="_blank" rel="noreferrer noopener">to oral CGRP inhibitors</a>. </li>
<li>AXS-12 (reboxetine): Axsome previously announced the completion of its clinical program of AXS-12 in patients with narcolepsy with cataplexy. The company anticipates submitting an NDA to the FDA in the second half of 2025. </li>
<li>AXS-14 (esreboxetine): Axsome has submitted an NDA to the FDA for AXS-14 for fibromyalgia. The company anticipates the FDA&#8217;s decision on acceptance of the filing in the second quarter of 2025. </li>
<li>In April, Axsome announced topline results from the PARADIGM Phase 3 proof-of-concept trial. The company plans to initiate a Phase 3 trial of solriamfetol in Major Depressive Disorder patients with excessive daytime sleepiness in 2025.</li>
</ul>
<h3 class="wp-block-heading">What&#8217;s Next</h3>
<ul>
<li>Axsome is conducting the ENGAGE Phase 3 study of solriamfetol in Binge Eating Disorder. The company anticipates topline results in 2026. </li>
<li>Axsome is conducting the SUSTAIN Phase 3 study in adults with Shift Work Disorder. Topline data is anticipated in 2026.</li>
</ul>
Price Action: AXSM stock is up 5.16% at $118 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Biotech

Earnings

Guidance

Health Care

General

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

WIIM

Axsome Therapeutics shares are trading higher after the company announced a better-than-expected Q1 financial results.

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(1.33) by 48.87 percent. This is a 32 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $121.46 million which beat the analyst consensus estimate of $119.87 million by 1.33 percent. This is a 61.95 percent increase over sales of $75.00 million the same period last year.

Earnings Beats

Axsome Therapeutics Q1 Adj. EPS $(0.68) Beats $(1.33) Estimate, Sales $121.46M Beat $119.87M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

In the latest quarter, 28 analysts provided ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">16</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $177.11, a high estimate of $216.00, and a low estimate of $133.00. Marking an increase of 9.75%, the current average surpasses the previous average price target of $161.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1745956875_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Axsome Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -63.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.26%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.38, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $190 to $193.

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $193

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy rating and announced a price target of $45. Ionis Pharmaceuticals shares closed at $27.09 on Friday. <a href="https://www.benzinga.com/quote/ions/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Tsai initiated coverage on Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy rating and announced a price target of $200. Axsome Therapeutics shares closed at $98.86 on Friday. <a href="https://www.benzinga.com/quote/axsm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst John Kilichowski initiated coverage on NETSTREIT Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with an Overweight rating and announced a price target of $18. Netstreit shares closed at $15.28 on Friday. <a href="https://www.benzinga.com/quote/ntst/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Youssef Squali initiated coverage on Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy rating and announced a price target of $150. Reddit shares closed at $86.91 on Friday. <a href="https://www.benzinga.com/quote/rddt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Greg Renza initiated coverage on BeiGene, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with an Outperform rating and announced a price target of $312. BeiGene shares closed at $238.51 on Friday.  <a href="https://www.benzinga.com/quote/onc/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying RDDT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="414" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-1024x414.png" alt="" class="wp-image-860270" style="width:465px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-1024x414.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07113723/image-67.png 1442w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Initiation

Markets

IONS

NTST

RDDT

This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Jefferies analyst Andrew Tsai initiates coverage on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy rating and announces Price Target of $200.

Jefferies Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $200

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

Axsome Therapeutics shares are trading lower after the company's Solriamfetol failed its primary goal in depression study but showed improvements in associated sleep disorder.

Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Tuesday released results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">daytime sleepiness (EDS)</a>.
In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared to placebo, the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44581422/axsome-therapeutics-announces-topline-results-of-paradigm-phase-3-proof-of-concept-trial-of-solria" rel="noreferrer noopener">study&#8217;s primary endpoint</a>.
In the prespecified subgroup of patients with severe EDS, treatment with solriamfetol resulted in greater improvements in depressive symptoms compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44475435/axsome-therapeutics-lower-dose-of-attention-deficient-disorder-candidate-hits-primary-goal" rel="noreferrer noopener">Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal</a>
The study was not powered to demonstrate statistical significance in the prespecified subgroups.
Based on the results in the EDS subgroup, Axsome plans to initiate a Phase 3 trial in MDD patients with EDS in 2025.
Solriamfetol was safe and well-tolerated in the trial, with a side effect profile consistent with the established safety profile.
William Blair notes that Axsome already sells Auvelity for MDD.
To prevent competition between its drugs, the company had planned to market solriamfetol specifically to MDD patients who also experience EDS, a common issue in MDD.
Because of this strategy, the limited efficacy signal in the EDS subgroup is not seen as a drawback for the drug's commercial potential.
While the positive results in MDD patients with severe EDS are promising and align with solriamfetol's known effects—it is already sold as Sunosi for EDS linked to obstructive sleep apnea—the PARADIGM study only included a small group of 51 patients.
Larger Phase 3 studies will be needed to confirm these findings.
Analyst Myles Minter writes, &#8220;Axsome remains our top pick for 2025. With focus for the company on Auvelity in MDD and an sNDA filing for Alzheimer's disease agitation (AD-A), we believe investor expectations were low for the PARADIGM study, and expect few had factored the opportunity into their valuations.&#8221;
Price Action: AXSM stock is down 4.41% at $111.49&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44585627/conagra-embraces-bloom-energys-fuel-cells-to-power-ohio-operations" target="_blank" rel="noreferrer noopener">Conagra Embraces Bloom Energy&#8217;s Fuel Cells To Power Ohio Operations</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $153 price target.

Needham Reiterates Buy on Axsome Therapeutics, Maintains $153 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) price target from $184 to $186. Wells Fargo analyst Jason Haas maintained an Underweight rating. Cintas shares closed at $204.71 on Wednesday. See how other <a href="https://www.benzinga.com/quote/CTAS/analyst-ratings">analysts view this stock</a>.</li>
<li>Mizuho raised the price target for Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from $212 to $216. Mizuho analyst Graig Suvannavejh maintained an Outperform rating. Axsome Therapeutics shares closed at $119.16 on Wednesday. <a href="https://www.benzinga.com/quote/AXSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) price target from $141 to $156. Stifel analyst Bryan Bergin maintained a Hold rating. Paychex shares closed at $150.19 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/PAYX/analyst-ratings">view this stock</a>.</li>
<li>Piper Sandler raised the price target for Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) from $56 to $59. Piper Sandler analyst Michael Lavery maintained a Neutral rating. Mondelez shares closed at $66.33 on Wednesday. <a href="https://www.benzinga.com/quote/MDLZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank increased the price target for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $70 to $75. Deutsche Bank analyst David Begleiter maintained a Buy rating. Celanese shares closed at $59.16 on Wednesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) price target from $240 to $215. Needham analyst Gerald Pascarelli maintained a Buy rating. Constellation shares settled at $184.11 on Wednesday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $230 to $260. B of A Securities analyst Tal Liani upgraded the stock from Neutral to Buy. Check Point Software shares closed at $227.87 on Wednesday. <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $75 to $82. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $69.21 on Wednesday.  <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from $135 to $120. Jefferies analyst Blayne Curtis downgraded the stock from Buy to Hold. AMD shares settled at $110.19 on Wednesday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) price target from $265 to $260. Wells Fargo analyst Christian Wetherbee maintained an Overweight rating. Union Pacific shares closed at $238.03 on Wednesday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44496478/top-2-industrials-stocks-that-may-crash-in-q1">Top 2 Industrials Stocks That May Crash In Q1</a></li>
</ul>

CHKP

CTAS

DLTR

MDLZ

PAYX

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) were provided by 31 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">18</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">10</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $168.71, along with a high estimate of $216.00 and a low estimate of $122.00. Marking an increase of 9.04%, the current average surpasses the previous average price target of $154.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1743080430_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Axsome Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Axsome Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Financial Milestones: Axsome Therapeutics's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -63.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.38. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $212 to $216.

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $216

On Tuesday, Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) announced that the FOCUS Phase 3 trial of solriamfetol for attention deficit hyperactivity disorder (ADHD) achieved its primary and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">key secondary endpoints</a>.
In the FOCUS study, 516 adults with ADHD were randomized to receive solriamfetol 150 mg, solriamfetol 300 mg, or placebo, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44470498/axsome-therapeutics-announces-focus-phase-3-trial-of-solriamfetol-in-adults-with-attention-deficit" rel="noreferrer noopener">once daily for 6 weeks</a>.
The study achieved the primary endpoint by demonstrating a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score compared to placebo at Week 6, with mean reductions from baseline of 17.7 points for solriamfetol 150 mg and 14.3 points for placebo (p=0.039).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" rel="noreferrer noopener">Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs</a>
Overall, the improvement with solriamfetol at Week 6 represents a 45% mean reduction from baseline in ADHD symptoms.
Improvements in the AISRS total score were greater with solriamfetol compared to placebo starting at Week 1 (p=0.036).
Clinical response, defined as ≥30% improvement from baseline in the AISRS total score, was achieved by a statistically significantly greater percentage of patients treated with solriamfetol 150 mg (53.5%) compared to those treated with placebo (41.3%) at Week 6 (p=0.024).
The study also achieved the key secondary endpoint by statistically significantly reducing overall ADHD disease severity compared to placebo, as assessed by the Clinical Global Impression of Severity (CGI-S) for ADHD, at Week 6 (p=0.017).
Results on the primary and key secondary endpoints for the exploratory 300 mg solriamfetol dose were numerically superior compared to placebo but were not statistically significant.
Solriamfetol was safe and well tolerated in the trial.
Price Action: AXSM stock is down 5.27% at $122.36 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44462549/lockheed-martin-stock-dips-as-bofa-analyst-lowers-eps-estimates-forecast-after-air-force-contract-setback" target="_blank" rel="noreferrer noopener">Lockheed Martin Stock Dips As BofA Analyst Lowers EPS Estimates, Forecast After Air Force Contract Setback</a></li>
</ul>

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal

Legal

Press Releases

ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions Survive Motions to Dismiss

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm

Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm

Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates Claims on Your Behalf

SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BIVI

DCGO

DRVN

MRCY

VIRT

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Axsome Therapeutics

매도 수량

Axsome Therapeutics (NASDAQ:AXSM) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌